Cargando…
Clinical Validation of Plasma-Based Genotyping for RAS and BRAF V600E Mutation in Metastatic Colorectal Cancer: SCRUM-Japan GOZILA Substudy
PURPOSE: Circulating tumor DNA (ctDNA) genotyping on the basis of next-generation sequencing (NGS) may guide targeted therapy for metastatic colorectal cancer (mCRC). However, the validity of NGS-based ctDNA genotyping for RAS/BRAF V600E mutation assessment and the efficacy of anti-EGFR and BRAF-tar...
Autores principales: | Aoki, Yu, Nakamura, Yoshiaki, Denda, Tadamichi, Ohta, Takashi, Esaki, Taito, Shiozawa, Manabu, Yamaguchi, Kensei, Yamazaki, Kentaro, Sunakawa, Yu, Kato, Takeshi, Okano, Naohiro, Taniguchi, Hiroya, Sato, Taro, Oki, Eiji, Nishina, Tomohiro, Komatsu, Yoshito, Matsuhashi, Nobuhisa, Goto, Masahiro, Yasui, Hisateru, Ohtsubo, Koushiro, Moriwaki, Toshikazu, Takahashi, Naoki, Horita, Yosuke, Boku, Shogen, Wakabayashi, Masashi, Ikeno, Takashi, Mitani, Ryuta, Yuasa, Mihoko, Yoshino, Takayuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10309506/ https://www.ncbi.nlm.nih.gov/pubmed/37343204 http://dx.doi.org/10.1200/PO.22.00688 |
Ejemplares similares
-
Clinical Validity of Plasma-Based Genotyping for Microsatellite Instability Assessment in Advanced GI Cancers: SCRUM-Japan GOZILA Substudy
por: Nakamura, Yoshiaki, et al.
Publicado: (2022) -
Efficacy of Targeted Trials and Signaling Pathway Landscape in Advanced Gastrointestinal Cancers From SCRUM-Japan GI-SCREEN: A Nationwide Genomic Profiling Program
por: Nakamura, Yoshiaki, et al.
Publicado: (2023) -
A Phase II Clinical Study of mFOLFOX6 Plus Bevacizumab as First-line Therapy for Japanese Advanced/Recurrent Colorectal Cancer Patients
por: Nishina, Tomohiro, et al.
Publicado: (2013) -
Multicenter phase II study of FOLFIRI plus bevacizumab after discontinuation of oxaliplatin-based regimen for advanced or recurrent colorectal cancer (CR0802)
por: Suenaga, Mitsukuni, et al.
Publicado: (2015) -
Role of plasma angiogenesis factors in the efficacy of first‐line chemotherapy combined with biologics in
RAS
wild‐type metastatic colorectal cancer: Results from the GI‐SCREEN CRC‐Ukit study
por: Yuki, Satoshi, et al.
Publicado: (2023)